# DESCRIPTION

## FIELD OF THE INVENTION

- relate to EGFR mutation testing and therapy development

## BACKGROUND OF THE INVENTION

- introduce EGFR and its role in cancer
- describe current therapies and limitations

## SUMMARY OF THE INVENTION

- introduce PCR primers for detecting EGFR mutant Câ†’T at position 2369
- describe method for detecting mutation in patients
- provide general primer structures
- describe PCR primer that hybridizes to wild type EGFR polypeptide
- describe PCR primer that hybridizes to mutant EGFR polypeptide
- describe method of detecting mutant EGFR gene in a sample
- describe alternative embodiments of detection method
- describe kit for detecting mutant EGFR gene

## DETAILED DESCRIPTION OF THE INVENTION

- incorporate references
- define abbreviations
- provide accession numbers
- explain numbering systems for EGFR
- define terms "tumor" and "cancer"
- describe examination of EGFR exons
- describe analysis of KRAS mutations
- characterize drug sensitivity of EGFR mutants
- display cDNA sequence of mutant human EGFR gene
- describe nucleic acid and polynucleotide terms
- define oligonucleotide terms
- explain nucleotide sequence and polynucleotide sequence terms
- describe modified or derivatized nucleotides
- provide examples of modified bases
- describe linkages between nucleotides
- define "complement" and related terms
- define "liberate" in relation to nucleic acids
- define "hybridize" and related terms
- define cleaving means
- describe complementary DNA
- outline methods for detecting EGFR T790M mutation
- describe diagnostic kit for detecting mutant EGFR T790M
- illustrate primer sequences
- describe synthesis of polynucleotides
- outline methods for synthesizing oligonucleotides
- describe amplification process
- outline methods for isolating nucleic acid specimens
- describe DNA polymerization agents
- outline methods for detecting amplification products
- describe evaluation of amplified sequences
- outline alternative methods of amplification
- describe nucleic acid sequence-based amplification
- outline ligase chain reaction
- describe repair chain reaction
- outline strand displacement activation
- describe QB Replicase System
- outline allele specific hybridization
- describe membrane-based formats for ASO analysis

### Designing an Allele Specific Oligonucleotide (ASO) Probe

- define ASO probe
- design requirements of ASO probe
- limitations of ASO probe design
- application of ASO probe in dot blot
- alternative methods for large scale screening
- describe DNA chip technology
- embodiment of diagnosing cancer relapse
- other methods of DNA sequencing
- describe diagnostic kit preparation
- application of antibody in cancer diagnosis

## EXAMPLES

### Materials and Methods

- obtain tumor specimens
- perform mutational analyses of EGFR and KRAS
- conduct RT-PCR
- perform functional analyses of mutant EGFRs
- conduct immunoblotting
- perform cell culture
- conduct viability assay

### Example 1

- confirm presence of EGFR T790M mutation

### Clonal Origin of the EGFR T790M Mutation

- demonstrate clonal origin of EGFR T790M mutation

### Assay for the EGFR T790M Mutation in Genomic DNA

- detect EGFR T790M mutation using PCR-RFLP

### Case Reports

- present case history of patient 1
- present case history of patient 2
- present case history of patient 3

### Example 5

- screen patients' tumors for EGFR mutations
- identify EGFR mutations associated with sensitivity to tyrosine kinase inhibitors
- analyze tumor samples from three patients for EGFR mutations
- detect EGFR mutations in all three patients
- analyze tumor samples for secondary mutations in EGFR kinase domain
- detect T790M mutation in patients with progressing disease
- analyze tumor samples from additional patients with acquired resistance
- find T790M mutation in some patients with acquired resistance
- rule out KRAS mutations as cause of acquired resistance
- analyze EGFR mutations in established NSCLC cell lines
- find T790M mutation in one NSCLC cell line (H1975)
- develop PCR-RFLP assay to detect T790M mutation
- use PCR-RFLP assay to confirm T790M mutation in patient samples
- introduce T790M mutation into EGFR cDNAs with other mutations
- analyze biochemical properties of EGFR mutants
- find that T790M mutation impairs ability of gefitinib or erlotinib to inhibit EGFR tyrosine kinase activity
- determine sensitivity of NSCLC cell lines to gefitinib or erlotinib

